natgillin/translations-raw huggingface dataset:
Rare: may affect up to 1 in 1,000 people - infection - decreased number of all blood cell types - severe allergic reactions (DRESS, anaphylactic reaction [severe and important allergic reaction], Quincke's oedema [swelling of the face, lips, tongue and throat])) - decreased blood sodium concentration - suicide, personality disorders (behavioural problems), thinking abnormal (slow thinking, unable to concentrate) - delirium - encephalopathy (see sub-section “Tell your doctor immediately” for a detailed description of symptoms) - uncontrollable muscle spasms affecting the head, torso and limbs, difficulty in controlling movements, hyperkinesia (hyperactivity) - pancreatitis - liver failure, hepatitis - sudden decrease in kidney function - skin rash, which may form blisters and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme), a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (StevensJohnson syndrome), and a more severe form causing skin peeling in more than 30% of the body surface (toxic epidermal necrolysis) rhabdomyolysis (breakdown of muscle tissue) and associated blood creatine phosphokinase increase. 
angioedem [oticanje lica, usana, jezika i grla]) - snižena koncentracija natrija u krvi - samoubojstvo, poremećaj osobnosti (problemi u ponašanju), poremećaj mišljenja (sporo razmišljanje, nemogućnost koncentriranja) - delirij - oštećenje mozga (encefalopatija, za detaljan opis simptoma pogledajte podnaslov (vidjeti pododjeljak „Recite odmah svom liječniku“ za detaljni opis simptoma) - nekontrolirani mišićni grčevi koji zahvaćaju glavu, trup i udove, teškoće u kontroliranju pokreta, hiperkinezija (hiperaktivnost) - upala gušterače - zatajenje jetre, hepatitis - iznenadno smanjenje bubrežne funkcije
Levetiracetam SUN is not indicated in children and adolescents below 16 years on its own (monotherapy). 
Djeca i adolescenti - U djece i adolescenata mlađih od 16 godina Levetiracetam SUN se ne primjenjuje samostalno
15 minutes Twice daily 1000 mg/day 
15 minuta Dva puta na dan 1000 mg/dan
Detailed information on this medicine is available on the European Medicines Agency web site: 
Detaljnije informacije o ovom lijeku dostupne su na internetskim stranicama Europske agencije za lijekove http://www.ema.europa.eu
Levetiracetam SUN may impair your ability to drive or operate any tools or machinery, as it may make you feel sleepy. 
Ako vozite ili upravljate alatima ili vozilima potreban je oprez jer se pri uzimanju Levetiracetam SUN-a može javiti osjećaj pospanosti.
Intravenous use. 
Za primjenu u venu
NAME OF THE MEDICINAL PRODUCT Levetiracetam SUN 100 mg/ml concentrate for solution for infusion levetiracetam 
Levetiracetam SUN 100 mg/ml koncentrat za otopinu za infuziju levetiracetam
Table 1. 
Kubickiego 11
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal product subject to medical prescription. 
PRILOG II A. PROIZVOĐAČ ODGOVORAN ZA PUŠTANJE SERIJE LIJEKA U PROMET B. UVJETI ILI OGRANIČENJA VEZANI UZ OPSKRBU I PRIMJENU C. OSTALI UVJETI I ZAHTJEVI ODOBRENJA ZA STAVLJANJE GOTOVOG LIJEKA U PROMET D. UVJETI ILI OGRANIČENJA VEZANI UZ SIGURNU I UČINKOVITU PRIMJENU LIJEKA
STATEMENT OF ACTIVE SUBSTANCE(S) One vial contains 500 mg/5 ml levetiracetam. 
TVARI Jedna bočica sadrži 500 mg/5 ml levetiracetama.
Wash hands after handling the product. 
Oprati ruke nakon rukovanja proizvodom.
ATCvet code: QP53BE04 
ATCvet kod: QP53BE04
These signs typically resolve without treatment. 
Ovi znakovi obično prolaze bez liječenja.
Food enhances the absorption. 
Hrana potiče apsorpciju.
The terminal half-life is approximately 4 weeks. 
Terminalni poluživot iznosi oko 4 tjedna.
Due to insufficient data to support efficacy against ticks in young cats, this product is not recommended for the treatment of ticks in kittens 5 months of age or younger. 
Uslijed nedostatnih podataka za potporu učinkovitosti protiv krpelja kod mladih mačaka, ovaj se proizvod ne preporučuje za liječenje protiv krpelja kod mačića starosti 5 mjeseci ili mlađih.
10 DATE OF REVISION OF THE TEXT <{DD/MM/YYYY}> 
DATUM REVIZIJE TEKSTA <{DD/MM/GGGG}>
Each chewable tablet contains: 
Svaka tableta za žvakanje sadržava:
Crospovidone 
Krospovidon
Administer with or after food. 
Primijeniti uz ili nakon obroka.
1 tablet 3 tablets 6 tablets 
1 tableta 3 tablete
Lotilaner is approximately 10 times more bioavailable when administered with food. 
Lotilaner ima otprilike 10 puta veću bioraspoloživost kad se primjenjuje uz obrok.
Appropriate combination of tablets 
Odgovarajuća kombinacija tableta
Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance. 
Buhe i krpelji se moraju pričvrstiti na domaćina i započeti hranjenje, kako bi mogli biti izloženi djelatnoj tvari.
The terminal half-life is approximately 4 weeks (harmonic mean). 
Terminalni poluživot iznosi oko 4 tjedna (harmonijska sredina).
The major route of elimination is biliary excretion, and renal excretion is the minor route of elimination (less than 10 % of the dose). 
Glavni put eliminacije je izlučivanje putem žuč, a izlučivanje putem bubrega manje je zastupljeni put eliminacije (manje od 10% doze).
Body weight of dog (kg) 
Tjelesna težina psa (kg)
Parasites need to start feeding on the host to become exposed to lotilaner; therefore the risk of the transmission of parasite borne diseases cannot be completely excluded. 
Paraziti moraju započeti hranjenje na domaćinu kako bi bili izloženi lotilaneru; zato se rizik od zaraznih bolesti koje prenose paraziti ne može isključiti.
Body weight of cat (kg) 
Tjelesna težina mačke (kg)
Strength and number of tablets to be administered 
Jačina i broj tableta koje treba davati
For optimal control of tick and flea infestations, the veterinary medicinal product should be administered at monthly intervals and continued throughout the flea and/or tick season based on local epidemiological situations. 
Za optimalnu kontrolu infestacija krpeljima i buhama, veterinarsko-medicinski proizvod treba primjenjivati u mjesečnim intervalima i nastaviti tijekom sezone buha i/ili krpelja na temelju lokalne epidemiološke situacije.
Do not use this veterinary medicinal product after the expiry date which is stated on the carton box and blister after EXP. 
Ne koristite veterinarsko-medicinski proizvod poslije isteka roka valjanosti naznačenog na kartonskoj kutiji i blisteru poslije EXP.
Elanco France S.A.S 26 Rue de la Chapelle 68330 Huningue FRANCE 
Elanco France S.A.S. 26 Rue de la Chapelle 68330 Huningue FRANCUSKA
Blisters (dogs) 
Blisteri (mačke)
The periodic safety update report (PSUR) cycle should be restarted for submission of 6 monthly reports (covering all authorised presentations of the product) for the next two years, followed by yearly reports for the subsequent two years and thereafter at 3 yearly intervals. 
(pokrivajući sva odobrena pakovanja proizvoda), u naredne dvije godine, nakon kojih slijede godišnja izvješća za sljedeće dvije godine, a nakon toga u trogodišnjim intervalima.
Credelio 900 mg chewable tablets for dogs: 2 years 
Credelio 900 mg tablete za žvakanje za pse: 2 godine
56 mg lotilaner 112 mg lotilaner 225 mg lotilaner 450 mg lotilaner 900 mg lotilaner 
lotilaner 56 mg lotilaner 112 mg lotilaner 225 mg lotilaner 450 mg lotilaner 900 mg
Credelio 56 mg, 112 mg, 225 mg, 450 mg chewable tablets for dogs: 3 years 
Credelio 56 mg, 112 mg, 225 mg, 450 mg tablete za žvakanje za pse: 3 godine
Lotilaner is a potent inhibitor of gamma-aminobutyric acid (GABA)-gated chloride channels, resulting in rapid death of ticks and fleas. 
Lotilaner je jak inhibitor kloridnih kanala reguliranih gama-aminomaslačnom kiselinom (GABA), što izaziva brzo ugibanje krpelja i buha.
Credelio chewable tablets lotilaner (mg) 
Credelio tablete za žvakanje lotilaner (mg)
NAME OF THE VETERINARY MEDICINAL PRODUCT Credelio 12 mg (0.5-2.0 kg) 
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA Credelio 12 mg (0,5-2,0 kg)
Therefore, the product breaks the flea life cycle and prevents environmental flea contamination in areas to which the cat has access. 
Dakle, proizvod prekida životni ciklus buha i sprječava kontaminaciju buhama, područja u koja mačka ima pristup.
This long terminal half-life provides effective blood concentrations for the entire duration of the interdosing interval. 
Tako dugi terminalni poluživot omogućuje djelotvornu koncentraciju u krvi tijekom cijelog razdoblja između dva doziranja.
The veterinary medicinal product kills existing and newly emerged fleas on cats before they can lay eggs. 
Veterinarsko-medicinski proizvod ubija buhe koje se već nalaze na mačkama i nove buhe prije nego stignu položiti jajašca.
This terminal half-life provides effective blood concentrations for the entire duration of the inter-dosing interval. 
Takav terminalni poluživot omogućuje djelotvornu koncentraciju u krvi tijekom cijelog razdoblja između dva doziranja.
MARKETING AUTHORISATION NUMBER(S) EU/2/17/206/016-21 
BROJ(EVI) ODOBRENJA ZA STAVLJANJE U PROMET EU/2/17/206/016-21
For cats of more than 8 kg body weight, use an appropriate combination of available strengths to achieve the recommended dose of 6-24 mg/kg. 
Za mačke teže od 8 kg upotrijebite odgovarajuću kombinaciju raspoloživih jačina tableta kako biste postigli preporučenu dozu od 6 do 24 mg/kg.
Shelf life of the veterinary medicinal product as packaged for sale: 
Rok valjanosti veterinarsko-medicinskog proizvoda kad je zapakiran za prodaju:
Therefore, the product breaks the flea life cycle and prevents environmental flea contamination in areas to which the dog has access. 
Dakle, proizvod prekida životni ciklus buha i sprječava kontaminaciju buhama, područja u koja pas ima pristup.
The veterinary medicinal product kills existing and newly emerged fleas on dogs before they can lay eggs. 
Veterinarsko-medicinski proizvod ubija buhe koje se već nalaze na psima i nove buhe prije nego stignu položiti jajašca.
Laboratory studies in rats have not produced any evidence of teratogenic effects, or any adverse effect on the reproductive capacity of males and females. 
Laboratorijski pokusi na štakorima nisu izazvali nikakav teratogeni učinak niti bilo kakav negativan učinak na reproduktivnu sposobnost ženki i mužjaka.
- very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports). 
- manje česte (više od 1 ali manje od 10 životinja na 1.000 tretiranih životinja) - rijetke (više od 1 ali manje od 10 životinja na 10.000 tretiranih životinja)
Lotilaner is metabolized to a small extent into more hydrophilic compounds which are observed in faeces and urine. 
Lotilaner se u maloj mjeri metabolizira u hidrofilne spojeve koji se primjećuju stolici i urinu.
Laboratory studies in rats have not produced any evidence of teratogenic effects. 
Laboratorijski pokusi na štakorima nisu izazvali nikakav teratogeni učinak.
Pharmacotherapeutic group: ectoparasiticides for systemic use, isoxazolines. 
Farmakoterapijska grupa: ektoparazitici, za sustavnu primjenu, izoksazolini.
Manufacturer responsible for batch release: Elanco France S.A.S., 26 rue de la Chapelle, 68330 Huningue, France 
Elanco France S.A.S., 26 rue de la Chapelle, 68330 Huningue, Francuska
Use only according to the benefit/risk assessment by the responsible veterinarian. 
Upotrijebiti samo u skladu s procjenom koristi/rizika od strane odgovornog veterinara.
Following oral administration, lotilaner is readily absorbed and peak blood concentration is reached at 4 hours. 
Nakon primjene kroz usta, lotilaner se odmah apsorbira, a vršna koncentracija u krvi postiže se u roku od 4 sata.
Following oral administration, lotilaner is readily absorbed and peak blood concentration is reached within 2 hours. 
Nakon primjene kroz usta, lotilaner se odmah apsorbira, a vršna koncentracija u krvi postiže se u roku od 2 sata.
MARKETING AUTHORISATION NUMBER(S) EU/2/17/206/001-015 
BROJ(EVI) ODOBRENJA ZA STAVLJANJE U PROMET EU/2/17/206/001-015
The tablets are packaged in aluminium/aluminium blisters packaged into an outer cardboard box. 
6.5 Osobine i sastav unutarnjeg pakovanja Tablete se nalaze u aluminijskim/aluminijskim blisterima, pakiranim u kartonskoj kutiji.
The product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD). 
Proizvod se može primjenjivati kao dio strategije liječenja u kontroli alergijskog dermatitisa uzrokovanog buhama (FAD).
Sodium laurilsulfate Vanillin (flavour) 
Natrijev laurilsulfat
Use an appropriate combination of available strengths to achieve the recommended dose of 2043 mg/kg. 
Upotrijebite odgovarajuću kombinaciju raspoloživih jačina tableta kako biste postigli preporučenu dozu od 20 do 43 mg/kg.
EU/2/17/206/014 (900 mg lotilaner; 3 chewable tablets) EU/2/17/206/015 (900 mg lotilaner; 6 chewable tablets) 
EU/2/17/206/013 (lotilaner 900 mg; 1 tableta za žvakanje) EU/2/17/206/014 (lotilaner 900 mg; 3 tablete za žvakanje) EU/2/17/206/015 (lotilaner 900 mg; 6 tableta za žvakanje)
EU/2/17/206/001 (56 mg lotilaner; 1 chewable tablet) EU/2/17/206/002 (56 mg lotilaner; 3 chewable tablets) EU/2/17/206/003 (56 mg lotilaner; 6 chewable tablets) EU/2/17/206/004 (112 mg lotilaner; 1 chewable tablet) EU/2/17/206/005 (112 mg lotilaner; 3 chewable tablets) EU/2/17/206/006 (112 mg lotilaner; 6 chewable tablets) EU/2/17/206/007 (225 mg lotilaner; 1 chewable tablet) EU/2/17/206/008 (225 mg lotilaner; 3 chewable tablets) EU/2/17/206/009 (225 mg lotilaner; 6 chewable tablets) EU/2/17/206/010 (450 mg lotilaner; 1 chewable tablet) EU/2/17/206/011 (450 mg lotilaner; 3 chewable tablets) EU/2/17/206/012 (450 mg lotilaner; 6 chewable tablets) EU/2/17/206/013 (900 mg lotilaner; 1 chewable tablet) 
EU/2/17/206/001 (lotilaner 56 mg; 1 tableta za žvakanje) EU/2/17/206/002 (lotilaner 56 mg; 3 tablete za žvakanje) EU/2/17/206/003 (lotilaner 56 mg; 6 tableta za žvakanje) EU/2/17/206/004 (lotilaner 112 mg; 1 tableta za žvakanje) EU/2/17/206/005 (lotilaner 112 mg; 3 tablete za žvakanje) EU/2/17/206/006 (lotilaner 112 mg; 6 tableta za žvakanje) EU/2/17/206/007 (lotilaner 225 mg; 1 tableta za žvakanje) EU/2/17/206/008 (lotilaner 225 mg; 3 tablete za žvakanje) EU/2/17/206/009 (lotilaner 225 mg; 6 tableta za žvakanje) EU/2/17/206/010 (lotilaner 450 mg; 1 tableta za žvakanje) EU/2/17/206/011 (lotilaner 450 mg; 3 tablete za žvakanje) EU/2/17/206/012 (lotilaner 450 mg; 6 tableta za žvakanje)
Existing I. ricinus ticks on the animal prior to administration are killed within 8 hours. 
Postojeći I. ricinus krpelji koji se već nalaze na životinji prije primjene ugibaju u roku od 8 sati.
Lotilaner, a pure enantiomer from the isoxazoline class is active against fleas (Ctenocephalides felis and Ctenocephalides canis) as well as the tick species Dermacentor reticulatus, Ixodes hexagonus, Ixodes ricinus and Rhipicephalus sanguineus. 
Lotilaner, čisti enantiomer iz skupine izoksazolina aktivno djeluje protiv buha (Ctenocephalides felis i Ctenocephalides canis) i krpelja vrsta Dermacentor reticulatus, Ixodes hexagonus, Ixodes ricinus, Rhipicephalus sanguineus.
All safety and efficacy data have been acquired from dogs and puppies 8 weeks of age and older and 1.3 kg of body weight and greater. 
Svi podaci o neškodljivosti i djelotvornosti liječenja prikupljeni su od pasa i štenaca od 8 tjedana i starijih, teških 1,3 kg ili više.
The flavoured veterinary medicinal product should be administered in accordance with the following table to ensure a single dose of 6 to 24 mg lotilaner/kg bodyweight. 
Aromatiziran veterinarsko-medicinski proizvod treba davati u skladu sa sljedećom tablicom, kako bi se osiguralo jednokratno doziranje 6 do 24 mg lotilanera po kilogramu tjelesne težine.
Laboratory studies in rats have not produced any evidence of any adverse effect on the reproductive capacity of males and females. 
Laboratorijski pokusi na štakorima nisu izazvali nikakve nuspojave na reproduktivnu sposobnost ženki i mužjaka.
Each tablet strength is available in pack sizes of 1, 3 or 6 tablets. 
Pojedina jačina tablete dostupna je u pakiranjima od 1, 3 ili 6 tableta.
DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION For oral use. 
DOZIRANJE ZA SVAKU CILJNU VRSTU ŽIVOTINJA, NAČIN I PUT(EVI)
Administer the chewable tablet(s) monthly with or after food. 
Tabletu(e) za žvakanje dajte životinji jednom mjesečno uz obrok ili nakon njega.
During clinical testing, no interactions between Credelio chewable tablets and routinely used veterinary medicinal products were observed. 
Tijekom kliničkih ispitivanja nisu primijećene interakcije između tableta za žvakanje
The veterinary medicinal product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD). 
Veterinarsko-medicinski proizvod može se primjenjivati kao dio strategije liječenja u kontroli alergijskog dermatitisa uzrokovanog buhama (FAD).
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or label to the physician. 
U slučaju da se nehotice proguta, odmah potražiti pomoć liječnika i pokažite mu uputu o VMP ili etiketu.
PHARMACEUTICAL FORM Chewable tablet. 
OBLIK Tableta za žvakanje.
EU/2/17/206/016 (12 mg lotilaner; 1 chewable tablet) EU/2/17/206/017 (12 mg lotilaner; 3 chewable tablet) EU/2/17/206/018 (12 mg lotilaner; 6 chewable tablet) EU/2/17/206/019 (48 mg lotilaner; 1 chewable tablet) EU/2/17/206/020 (48 mg lotilaner; 3 chewable tablet) EU/2/17/206/021 (48 mg lotilaner; 6 chewable tablet) 
EU/2/17/206/016 (lotilaner 12 mg; 1 tableta za žvakanje) EU/2/17/206/017 (lotilaner 12 mg; 3 tablete za žvakanje) EU/2/17/206/018 (lotilaner 12 mg; 6 tableta za žvakanje) EU/2/17/206/019 (lotilaner 48 mg; 1 tableta za žvakanje) EU/2/17/206/020 (lotilaner 48 mg; 3 tablete za žvakanje) EU/2/17/206/021 (lotilaner 48 mg; 6 tableta za žvakanje)
Administer the veterinary medicinal product with food or within 30 minutes after feeding. 
Veterinarsko-medicinski proizvod dajte životinji uz obrok ili unutar 30 minuta nakon hranjenja.
The veterinary medicinal product should be administered in accordance with the following table to ensure a dose of 20 to 43 mg lotilaner/kg bodyweight. 
Veterinarsko-medicinski proizvod treba davati u skladu sa sljedećom tablicom, kako bi se osiguralo doziranje 20 do 43 mg lotilanera po kilogramu tjelesne težine.
for cats (0.5-2.0 kg) for cats (>2.0-8.0 kg) 
za mačke (0,5-2,0 kg) za mačke (> 2,0-8,0 kg)
All safety and efficacy data have been acquired from cats and kittens 8 weeks of age and older and 0.5 kg of body weight and greater. 
Svi podaci o neškodljivosti i djelotvornosti liječenja prikupljeni su od mačaka i mačića od 8 tjedana i starijih, teških 0,5 kg ili više.
PHARMACEUTICAL FORM Chewable tablet 
OBLIK Tableta za žvakanje
for cats (0.5-2.0 kg) for cats (>2-8.0 kg) 
za mačke (0,5 - 2,0 kg) za mačke (> 2,0 - 8,0 kg)
For the treatment of flea and tick infestations on cats. 
Za liječenje infestacije buhama i krpeljima na mačkama.
The safety of the veterinary medicinal product in cats has not been established during pregnancy and lactation. 
Neškodljivost veterinarsko-medicinskog proizvoda kod mačaka nije utvrđena tijekom graviditeta i laktacije.
Each strength of Credelio chewable tablets for cats is available in pack sizes of 1, 3 or 6 tablets. 
Credelio tableta za žvakanje za mačke dostupne su u pakiranjima od 1, 3 ili 6 tableta.
Fleas on the animal prior to administration are killed within 6 hours. 
Buhe koje se već nalaze na životinji prije liječenja ubijaju se u roku od 6 sati.
This veterinary medicinal product provides immediate and persistent killing activity for 1 month against fleas (Ctenocephalides felis and C. canis) and ticks (Ixodes ricinus). 
Veterinarsko-medicinski proizvod trenutačno i postojano ubija buhe (Ctenocephalides felis i C. canis)
White to beige round chewable tablets with brownish spots. 
Okrugle tablete za žvakanje, bijele do bež boje, sa smećkastim mrljama.
The activity of lotilaner was not affected by resistance to organochlorines (cyclodienes, e.g. dieldrin), phenylpyrazoles (e.g. fipronil), neonicotinoids (e.g. imidacloprid), formamidines (e.g. amitraz) and pyrethroids (e.g. cypermethrin). 
Na djelovanje lotilanera nije utjecala otpornost na organoklorne spojeve (ciklodiene, npr. dieldrin), fenilpirazole (npr. fipronil), neonikotinoide (npr. imidakloprid), formamidine (npr. amitraz) i piretroide (npr. cipermetrin).
Mild and transient gastrointestinal effects such as vomiting and diarrhoea have been reported to occur very rarely based on post-marketing safety experience. 
NUSPOJAVE Nakon puštanja lijeka u promet, vrlo rijetko su prijavljene blage i prolazne posljedice po gastrointestinalni trakt poput povraćanja i proljeva.
STATEMENT OF ACTIVE SUBSTANCES 12 mg lotilaner 
SASTAV DJELATNIH TVARI lotilaner 12 mg lotilaner 48 mg
Each strength of Credelio chewable tablets is available in pack sizes of 1, 3 or 6 tablets. 
Credelio tableta za žvakanje dostupne su u pakiranjima od 1, 3 ili 6 tableta.
In in vitro studies, the activity of lotilaner against some arthropod species was not affected by resistance to organochlorines (cyclodienes, e.g. dieldrin), phenylpyrazoles (e.g. fipronil), neonicotinoids (e.g. imidacloprid), formamidines (e.g. amitraz) and pyrethroids (e.g. cypermethrin). 
In vitro ispitivanja djelovanja lotilanera protiv nekih artropodnih vrsta nije utjecala otpornost na organoklorne spojeve (ciklodiene, npr. dieldrin), fenilpirazole (npr. fipronil), neonikotinoide (npr. imidakloprid), formamidine (npr. amitraz) i piretroide (npr. cipermetrin).
Silicified microcrystalline cellulose Cellulose, powdered Lactose monohydrate Povidone K30 
Celuloza, prah Laktoza hidrat Povidon K30
Treatment of flea and tick infestations in dogs. 
Liječenje infestacije buhama i krpeljima kod pasa.
Fleas on the animal prior to administration are killed within 8 hours. 
Buhe koje se već nalaze na životinji prije liječenja ubijaju se u roku od 8 sati.
For the treatment of flea and tick infestations in dogs. 
Za liječenje infestacije buhama i krpeljima kod pasa.
Credelio is a palatable chewable flavoured tablet. 
Tablete Credelio ukusne su aromatizirane tablete za žvakanje.
Lotilaner, a pure enantiomer from the isoxazoline class, is active against fleas (Ctenocephalides felis and Ctenocephalides canis) and ticks (Ixodes ricinus). 
Lotilaner, čisti enantiomer iz skupine izoksazolina aktivno djeluje protiv buha (Ctenocephalides felis i
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) Each chewable tablet contains: Credelio chewable tablets lotilaner (mg) 
Svaka tableta za žvakanje sadrži: Credelio tablete za žvakanje lotilaner (mg)
No adverse reactions were observed following oral administration to puppies aged 8-9 weeks and weighing 1.3-3.6 kg treated with overdoses of up to 5 times the maximum recommended dose (43 mg, 129 mg and 215 mg lotilaner/kg bodyweight) on eight occasions at monthly intervals. 
Nikakve negativne reakcije nisu primijećene prilikom primjene kroz usta, na štencima starim 8 - 9 tjedana, težine 1,3 - 3,6 kg, koji su predozirani dozama koje su bile do 5 puta veće od maksimalno preporučene doze (43 mg, 129 mg i 215 mg lotilanera po kilogramu tjelesne težine) u osam navrata, u razmacima od mjesec dana.
for dogs (1.3-2.5 kg) for dogs (>2.5-5.5 kg) for dogs (>5.5-11 kg) for dogs (>11-22 kg) for dogs (>22-45 kg) 
za pse (1,3-2,5 kg) za pse (> 2,5-5,5 kg) za pse (> 5,5-11 kg) za pse (> 11-22 kg) za pse (> 22-45 kg)
For oral use. 
SAVIJETI ZA ISPRAVNU PRIMJENU
The safety of the veterinary medicinal product in breeding dogs has not been established. 
Neškodljivost veterinarsko-medicinskog proizvoda kod pasa namijenjenih za uzgoj nije utvrđena.
PACKAGE LEAFLET: Credelio 12 mg chewable tablets for cats (0.5-2.0 kg) Credelio 48 mg chewable tablets for cats (>2.0-8.0 kg) 
Credelio 12 mg tablete za žvakanje za mačke (0,5-2,0 kg) Credelio 48 mg tablete za žvakanje za mačke (> 2,0-8,0 kg)
10 DATE OF REVISION OF THE TEXT DD/MM/YYYY 
DD/MM/GGGG